scholarly journals Long-term quality of life among Dutch prostate cancer survivors

Cancer ◽  
2006 ◽  
Vol 107 (9) ◽  
pp. 2186-2196 ◽  
Author(s):  
Floortje Mols ◽  
L. V. van de Poll-Franse ◽  
A. J. J. M. Vingerhoets ◽  
A. Hendrikx ◽  
N. K. Aaronson ◽  
...  
2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 9594-9594
Author(s):  
Anne-Valérie Guizard ◽  
Clarisse Kerleau ◽  
Pascale Grosclaude ◽  
Mariette Mercier ◽  
Natacha Heutte ◽  
...  

2016 ◽  
Vol 63 ◽  
pp. 143-153 ◽  
Author(s):  
Clarisse Kerleau ◽  
Anne-Valérie Guizard ◽  
Laetitia Daubisse-Marliac ◽  
Natacha Heutte ◽  
Mariette Mercier ◽  
...  

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 9044-9044
Author(s):  
D. J. Storey ◽  
D. McLaren ◽  
M. Shipway ◽  
I. Butcher ◽  
S. Liggatt ◽  
...  

9044 Background: In the absence of definitive evidence of best disease control, treatment decisions for early prostate cancer should consider likely long term side effects and quality of life. Fatigue is an acute side effect of treatment but there are no data about long term clinically significant fatigue (CSF) in recurrence free prostate cancer survivors. This study presents the prevalence, associations and predictors of CSF after radical prostatectomy (RP) or radiotherapy (XRT). Methods: A postal questionnaire survey of 416 recurrence free men treated at a regional cancer centre >1 year previously. CSF was defined as global Brief Fatigue Inventory score >3. Other measures: Hospital Anxiety and Depression Scale (HADS), International Prostate Symptom Score (IPSS), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, clinical and demographic information. Relationships between these factors and CSF were explored in univariate and then multivariate logistic regression analyses. Results: 91% (377/416) of questionnaires were analyzable. Mean age was 72 years (SD 6.1) and median time since treatment was 56 months (range 13–233). The prevalence of CSF was 29% (108/377) overall; 22% (29/133) post RP and 33% (79/244) post XRT. Univariate and multivariate associations of CSF predictors are shown below. Patients with CSF also had poorer quality of life, physical, role, and social function (all p<0.001). CSF was not associated with age, social deprivation category or time since treatment. Conclusions: Almost a third of recurrence free prostate cancer survivors have CSF. RP is associated with less CSF post treatment than XRT, but treatment type did not remain statistically significant in a multivariate analysis controlling for other factors. Depression at outcome had the strongest association with CSF. Other associated variables were IPSS>7, comorbid medical conditions and anxiety. Care should focus on optimising the identification and management of these conditions to improve fatigue. [Table: see text] No significant financial relationships to disclose.


Urology ◽  
2014 ◽  
Vol 84 (2) ◽  
pp. 300-306 ◽  
Author(s):  
Kimberly M. Davis ◽  
Scott P. Kelly ◽  
George Luta ◽  
Catherine Tomko ◽  
Anthony B. Miller ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document